|
[1] HERNANDEZ-GEA V,de GOTTARDI A,LEEBEEK FWG,et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis[J]. J Hepatol,2019,71(1):175-199.
|
|
[2] DING PX,HAN XW,LIU C,et al. Long-term outcomes of individualized treatment strategy in treatment of type I BuddChiari syndrome in 456 patients[J]. Liver Int,2019,39(8):1577-1586.
|
|
[3] MUKUND A,SARIN SK. Budd-Chiari syndrome:A focussed and collaborative approach[J]. Hepatol Int,2018,12(6):483-486.
|
|
[4] KHAN F,ARMSTRONG MJ,MEHRZAD H,et al. Review article:A multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome[J]. Aliment Pharmacol Ther,2019,49(7):840-863.
|
|
[5] LI J,MA XX,SUN YL,et al. Establishment of Budd-Chiari syndrome model in rat[J]. Chin J Bases Clin General Surg,2013,20(5):477-480.(in Chinese)李健，马秀现，孙玉岭，等．布-加综合征大鼠动物模型的建立[J]．中国普外基础与临床杂志，2013,20(5):477-480.
|
|
[6] QI X,HAN G,GUO X,et al. Review article:The aetiology of primary Budd-Chiari syndrome-differences between the West and China[J]. Aliment Pharmacol Ther,2016,44(11-12):1152-1167.
|
|
[7] WU KM,CAO S,ZHANG GY,et al. A case of paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome as the first manifestation[J]. J Clin Hepatol,2018,34(10):2197-2199.(in Chinese)巫凯敏，曹珊，张国艳，等．以布加综合征为首发表现的阵发性睡眠性血红蛋白尿症1例报告[J]．临床肝胆病杂志，2018,34(10):2197-2199.
|
|
[8] LIU DH,XIA XW,YE TH,et al. The effect of CT/MR in evaluating obstructive characteristics and interventional therapy related risk factors in patients with inferior vena cava obstruction[J]. Diagn Imag Interv Radiol,2019,28(1):21-26.(in Chinese)刘德翰，夏向文，叶天和，等．下腔静脉梗阻的CT/MR特征与介入治疗相关危险因素评估[J]．影像诊断与介入放射学，2019,28(1):21-26.
|
|
[9] WANG QH,LI K,HE CY,et al. Angioplasty with versus without routine stent placement for Budd-Chiari syndrome:A randomised controlled trial[J]. Lancet Gastroenterol Hepatol,2019,4(9):686-697.
|
|
[10] QI XS,REN WR,FAN DM,et al. Selection of treatment modalities for Budd-Chiari Syndrome in China:A preliminary survey of published literature[J]. World J Gastroenterol,2014,20(30):10628-10636.
|
|
[11] HAYEK G,RONOT M,PLESSIER A,et al. Long-term outcome and analysis of dysfunction of transjugular intrahepatic portosystemic shunt placement in chronic primary BuddChiari syndrome[J]. Radiology,2017,283(1):280-292.
|
|
[12] SUN YL,MA XX,FENG LS,et al. Compensation by collateral circulation determines invasive therapeutic indications for patients with Budd-Chiari syndrome[J]. Gut,2012,61(12):1779-1780.
|
|
[13] FU Y,SUN YL,MA XX,et al. Necessity and indications of invasive treatment for Budd-Chiari syndrome[J]. Hepatobiliary Pancreat Dis Int,2011,10(3):254-260.
|
|
[14] VALLA DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J]. Hepatol Int,2018,12(Suppl 1):168-180.
|
|
[15] MAGUIRE R,DOPPMAN JL. Angiographic abnormalities in partial Budd-Chiari syndrome[J]. Radiology,1977,122(3):629-635.
|
|
[16] BAI DQ,ZHAN F,ZHENG Y. An animal model with ascites due to hepatic vein resistance[J]. Chin J Lab Anim Sci,2002,12(1):28-30.(in Chinese)白殿卿，詹峰，郑颖．犬肝静脉阻力制做腹水实验模型的改进[J]．中国实验动物学杂志，2002,12(1):28-30.
|
|
[17] WANG CX,LIANG FQ,HAN LN,et al. Establishment of the Budd-Chiari syndrome model through laser photocoagulation[J]. Chin J Laser Med Surg,2005,14(1):9-11.(in Chinese)王春喜，梁发启，韩丽娜，等．利用腔内激光技术制作肝静脉阻塞性布加氏综合征模型的探讨[J]．中国激光医学杂志，2005,14(1):9-11.
|
|
[18] CHEN SY,GAO Y,YU CW,et al. A canine model for IVC occlusive form of Budd-Chiari syndrome using endovascular technique[J]. Cell Biochem Biophys,2013,67(3):1513-1519.
|
|
[19] SHEN B,ZHANG QQ,WANG XL,et al. Development of a canine model with diffuse hepatic vein obstruction(Budd-Chiari syndrome)via endovascular occlusion[J]. Mol Med Rep,2014,9(2):607-613.
|
|
[20] MURAD SD,DOM VA,RITMAN EL,et al. Early changes of the portal tract on microcomputed tomography images in a newly-developed rat model for Budd-Chiari syndrome[J].J Gastroenterol Hepatol,2008,23(10):1561-1566.
|
|
[21] CHENG DL,ZHU N,LI CL,et al. Significance of malondialdehyde,superoxide dismutase and endotoxin levels in Budd-Chiari syndrome in patients and a rat model[J]. Exp Ther Med,2018,16(6):5227-5235.
|
|
[22] GAO B,LI C,LIU P. Establishment of a mouse model of acute Budd-Chiari syndrome and expression of protease-activated receptor-1 in liver,spleen and kidneytissues[J]. J Med Pest Control,2019,35(12):1168-1172.(in Chinese)高兵，李晨，刘沛．急性布加综合征小鼠模型的建立及其肝脾肾组织中蛋白酶激活受体-1的表达[J]．医学动物防制，2019,35(12):1168-1172.
|
|
[23] CHENG DQ,ZHUANG YP,KOU QQ,et al. Numerical simulation of hemodynamics in membranous obstruction of the suprahepatic inferior vena cava based on a subject-specific Budd-Chiari syndrome model[J]. Clin Biomech(Bristol,Avon),2018,52:20-24.
|
|
[24] HO H,QIU C. Hemodynamic aspects of the Budd-Chiari syndrome of the liver:A computational model study[J]. Med Eng Phys,2019,69:134-139.
|
|
[25] TURJMAN AS,TURJMAN F,EDELMAN ER. Role of fluid dynamics and inflammation in intracranial aneurysm formation[J]. Circulation,2014,129(3):373-382.
|
|
[26] YAMAMOTO E,THONDAPU V,POON E,et al. Endothelial Shear stress and plaque erosion:A computational fluid dynamics and optical coherence tomography study[J]. JACC Cardiovasc Imaging,2019,12(2):374-375.
|
|
[27] CAZALS-HATEM D,VILGRAIN V,GENIN P,et al. Arterial and portal circulation and parenchymal changes in BuddChiari syndrome:A study in 17 explanted livers[J]. Hepatology,2003,37(3):510-519.
|
|
[28] MANCUSO A. Budd-Chiari syndrome hemodynamic:Clinical setting more complicated than computational model[J]. Med Eng Phys,2019,71:1.
|
DownLoad: